Montserrat Llanses
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Montserrat Llanses has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Eduard Batlle
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
26 shared publications - Hugh Sparks
Light Community, Department of Physics, Imperial College London, South Kensington Campus, London, SW7 2AZ, United Kingdom
25 shared publications - Julien Colombelli
Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
25 shared publications - Camille Stephan-Otto Attolini
Institute for Research in Biomedicine, Barcelona Institute of Science and Technology, Barcelona, Spain
24 shared publications - Carme Cortina
Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST) , c. Baldiri Reixac 10, 08028 Barcelona, Spain
24 shared publications Chris Dunsby
Light Community, Department of Physics, Imperial College London; The Francis Crick Institute
24 shared publications
Latest Publications
- 12 June 2026
- Published by EMBL-EBI
Multi-Site Reproducibility Study of 3D High-Content Analysis with Dual-View Oblique Plane Microscopy
BioStudies – one package for all the data supporting a study
- 12 June 2026
- Published by EMBL-EBI
Multi-Site Reproducibility Study of 3D High-Content Analysis with Dual-View Oblique Plane Microscopy
BioStudies – one package for all the data supporting a study
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S2. Hallmark, GOCC, KEGG and custom gene signatures of AKTP MTO, AKP CTO, PDO131, and PDO C31M. Selection related with Figure 2 (B, G, J, M)
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S2. Hallmark, GOCC, KEGG and custom gene signatures of AKTP MTO, AKP CTO, PDO131, and PDO C31M. Selection related with Figure 2 (B, G, J, M)
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S4 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S4 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S14 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Figures S1-S14 related to the manuscript "A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer"
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S14 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Figures S1-S14 related to the manuscript "A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer"
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S5 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S5 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Time-lapse imaging of representative AKTP MTO organoids from vehicle and RMC-9945 treatment conditions. Initial imaging (time 0h) was performed prior to vehicle or RMC-9945 treatment. Upon treatment, organoids were imaged every hour over a 48-hour period. Top (vehicle) and bottom (RMC-9945) panels show XY planes positioned at three z-depths relative to the centre of the organoids volume (-10 µm, 0 µm and +10 µm). Lgr5-EGFP is shown in green and Emp1-TOM in red. Scale bar, 50 µm.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Time-lapse imaging of representative AKTP MTO organoids from vehicle and RMC-9945 treatment conditions. Initial imaging (time 0h) was performed prior to vehicle or RMC-9945 treatment. Upon treatment, organoids were imaged every hour over a 48-hour period. Top (vehicle) and bottom (RMC-9945) panels show XY planes positioned at three z-depths relative to the centre of the organoids volume (-10 µm, 0 µm and +10 µm). Lgr5-EGFP is shown in green and Emp1-TOM in red. Scale bar, 50 µm.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Gene signatures used in Figure 1 (G, I, K), in Supplementary Figure S2, for the GSEA analysis in Figure 2 (B, G, J, M), in Supplementary Figure S5, in Figure 3 (A, B, C).
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Gene signatures used in Figure 1 (G, I, K), in Supplementary Figure S2, for the GSEA analysis in Figure 2 (B, G, J, M), in Supplementary Figure S5, in Figure 3 (A, B, C).
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S3. Gene expression related to Supplementary Figure S6B, C, G, H, I, J
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Supplementary Table S3. Gene expression related to Supplementary Figure S6B, C, G, H, I, J
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Dependency on Lgr5+ CSCs in RMC-9945–treated metastases. A, Relative mRNA expression of Gfp and Lgr5 genes in sorted GFP-high, -medium, -low, and -negative population from AKTP MTO-derived liver metastases. Mean ± SEM. B, Schematics of in vivo RMC-9945 treatment (7 days, starting at day 21 after implantation), Diphtheria toxin (DT) treatment (one injection any other day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. C, Representative histograms of Lgr5-EGFP expression of the EPCAM+/CD45− population in mice treated with vehicle, RMC-9945, DT, and RMC-9945 + DT obtained by flow cytometry. D, Representative pictures of livers after 7 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. E and F, Quantifications of total number of metastases per mouse in each condition described (E) and of the proportion of metastases per size (higher diameter; F). Vehicle n = 5 mice, RMC-9945 n = 10, DT n = 8, and RMC-9945 + DT = 7. Mean ± SEM. For E, P values are derived from ANOVA followed by Tukey tests. For F, P values are derived from the β-binomial regression model. G, Schematics of in vivo RMC-9945 treatment (10 days, starting at day 15 after implantation), DT treatment (one injection every day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. H and I, Quantifications of total number of metastases per mouse in each condition described (H) and of the proportion of metastases per size (higher diameter; I). Vehicle n = 8 mice, RMC-9945 n = 12, DT n = 8, and RMC-9945 + DT = 12. Mean ± SEM. For H, P values are derived from ANOVA followed by Dunnett tests. For I, P values are derived from the β-binomial regression model. J, Representative pictures of livers after 10 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. K, Kaplan–Meier survival plot of mice treated with the indicated treatments. P values are derived from Gehan–Breslow–Wilcoxon test.
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Dependency on Lgr5+ CSCs in RMC-9945–treated metastases. A, Relative mRNA expression of Gfp and Lgr5 genes in sorted GFP-high, -medium, -low, and -negative population from AKTP MTO-derived liver metastases. Mean ± SEM. B, Schematics of in vivo RMC-9945 treatment (7 days, starting at day 21 after implantation), Diphtheria toxin (DT) treatment (one injection any other day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. C, Representative histograms of Lgr5-EGFP expression of the EPCAM+/CD45− population in mice treated with vehicle, RMC-9945, DT, and RMC-9945 + DT obtained by flow cytometry. D, Representative pictures of livers after 7 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. E and F, Quantifications of total number of metastases per mouse in each condition described (E) and of the proportion of metastases per size (higher diameter; F). Vehicle n = 5 mice, RMC-9945 n = 10, DT n = 8, and RMC-9945 + DT = 7. Mean ± SEM. For E, P values are derived from ANOVA followed by Tukey tests. For F, P values are derived from the β-binomial regression model. G, Schematics of in vivo RMC-9945 treatment (10 days, starting at day 15 after implantation), DT treatment (one injection every day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. H and I, Quantifications of total number of metastases per mouse in each condition described (H) and of the proportion of metastases per size (higher diameter; I). Vehicle n = 8 mice, RMC-9945 n = 12, DT n = 8, and RMC-9945 + DT = 12. Mean ± SEM. For H, P values are derived from ANOVA followed by Dunnett tests. For I, P values are derived from the β-binomial regression model. J, Representative pictures of livers after 10 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. K, Kaplan–Meier survival plot of mice treated with the indicated treatments. P values are derived from Gehan–Breslow–Wilcoxon test.
- Open Access
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Gene signatures used in Figure 1 (G, I, K), in Supplementary Figure S2, for the GSEA analysis in Figure 2 (B, G, J, M), in Supplementary Figure S5, in Figure 3 (A, B, C).
- 6 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer
Gene signatures used in Figure 1 (G, I, K), in Supplementary Figure S2, for the GSEA analysis in Figure 2 (B, G, J, M), in Supplementary Figure S5, in Figure 3 (A, B, C).